Neuronetics Stock News

MALVERN, Pa., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM ), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that Keith Sullivan, President and Chief Executive Officer, and Steve Furlong, Senior Vice President, Chief Financial Officer, and Treasurer, will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference. A Full story available on Benzinga.com

Neuronetics, Inc. (NASDAQ:STIM) was the recipient of a large decrease in short interest in the month of October. As of October 29th, there was short interest totalling 979,800 shares, a decrease of 18.4% from the October 14th total of 1,200,000 shares. Currently, 4.0% of the companys stock are short sold. Based on an average daily []

Neuronetics, Inc. (NASDAQ:STIM) Director Bruce Joseph Shook sold 7,797 shares of the stock in a transaction on Friday, November 12th. The shares were sold at an average price of $5.30, for a total value of $41,324.10. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Shares []

JPMorgan Chase & Co. increased its holdings in shares of Neuronetics, Inc. (NASDAQ:STIM) by 59,931.3% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 9,605 shares of the companys stock after purchasing an additional 9,589 shares during the quarter. JPMorgan Chase & Co.s holdings []

Zacks Investment Research cut shares of Neuronetics (NASDAQ:STIM) from a hold rating to a sell rating in a report issued on Saturday morning, Zacks.com reports. According to Zacks, Neuronetics, Inc. is a commercial-stage medical device company. It focused on designing, developing, and marketing products for patients who suffer from psychiatric disorders. NeuroStar Advanced Therapy System(R), []

Neuronetics, Inc. (NASDAQ:STIM) Equities research analysts at William Blair reduced their FY2021 EPS estimates for Neuronetics in a research note issued to investors on Tuesday, November 9th. William Blair analyst M. Kaczor now anticipates that the company will post earnings per share of ($1.25) for the year, down from their previous estimate of ($1.12). []

Neuronetics, Inc. (STIM) CEO Keith Sullivan on Q3 2021 Results - Earnings Call Transcript

System Innovations Improve Efficiencies for Healthcare Practices and Patients

LOS ANGELES--(BUSINESS WIRE)---- $STIM #investors--The Law Offices of Frank R. Cruz Announces Investigation of Neuronetics, Inc. (STIM) on Behalf of Investors

MALVERN, Pa., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing and marketing products that improve the

MALVERN, Pa., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing and marketing products that improve the

Efforts feature mental health advocate and expert Dr. Melissa Shepard Efforts feature mental health advocate and expert Dr. Melissa Shepard

Peer-Reviewed Paper is Largest Real-World Data Set of TMS Seizure Risk Across Device Manufacturers Peer-Reviewed Paper is Largest Real-World Data Set of TMS Seizure Risk Across Device Manufacturers

Peer-Reviewed Paper is Largest Real-World Data Set of TMS Seizure Risk Across Device Manufacturers Peer-Reviewed Paper is Largest Real-World Data Set of TMS Seizure Risk Across Device Manufacturers

Industry-changing partnership will increase patient access to NeuroStar® Advanced Therapy for Mental Health Industry-changing partnership will increase patient access to NeuroStar® Advanced Therapy